# Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)

> **NCT03588715** · PHASE1 · UNKNOWN · sponsor: **Luis Montaner** · enrollment: 15 (actual)

## Conditions studied

- HIV
- HIV/AIDS
- HIV-1 Infection

## Interventions

- **DRUG:** Pegylated Interferon alpha 2b (peg-IFN-α2b)
- **DRUG:** 3BNC117 + 10-1074

## Key facts

- **NCT ID:** NCT03588715
- **Lead sponsor:** Luis Montaner
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-18
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-10-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-06-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03588715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03588715, "Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03588715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*